8
Oct
2024

Asamedic AS

Exhibitor at CPHI Milan 2024 stand 16G10, Finished Dosage Formulations
About Us

Asamedic is a Norwegian pharma company established in 2013 to develop a liquid variant of ASA. Coxor has been approved in a European DCP and was launched with success in Norway in 2023. The product received great endorsement from KOLs, authorities, media and the public. Regulatory work for other continents is ongoing. Asamedic is seeking licensing partners for European countries, as well as for other geographic regions. For more information, see contact section below. You can read more about Asamedic at www.asamedic.no and about Coxor on www.coxor.no

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • NO
  • 2024
    On CPHI since
  • 1
    Certificates
  • 1 - 24
    Employees
Company types
OTC
Primary activities
OTC
View company profile
Contact info
  • +4790546049
  • Website
  • Rosenholm Campus, Rosenholmveien 25, Postboks 474 Bedriftssenteret,, 1411, Kolbotn, Akershus, Norway
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 16G10, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • Coxor

    Product Coxor

    Coxor is a new drug formulation for treatment of acute heart attack. Heart attack is the no. 1 killer in the world, and no suited drug has been available for the public in spite of calls from scholars and KOLs on the subject. With Coxor, you have a liquid formulation with rapid onset-of action for the imme...